Specifically, we sought to determine the following: (1) the prevalence of NMDAR1-abs seropositivity in patients with severe stroke; (2) whether NMDAR1-abs seropositivity is a robust marker during the acute stroke phase; and (3) whether NMDAR1-abs titer levels remain stable across consecutive measurements. The gene discussed is GRIN1; the disease is stroke disorder.